Study on New Drug Combination for Colorectal Cancer
Author Information
Author(s): Garufi C, Bria E, Vanni B, Zappalà A M R, Sperduti I, Terzoli E
Primary Institution: Istituto Regina Elena, Roma, Italy
Hypothesis
Can the combination of irinotecan, oxaliplatin, 5-fluorouracil, and folinic acid improve treatment outcomes in advanced colorectal cancer patients?
Conclusion
The study found that the combination treatment is feasible with acceptable toxicity in heavily pretreated patients.
Supporting Evidence
- The combination of irinotecan and oxaliplatin showed activity in heavily pretreated patients.
- Patients experienced manageable side effects, primarily nausea and diarrhea.
- Overall response rate was 22.9%, with one complete response and seven partial responses.
Takeaway
Doctors tested a new mix of medicines to help people with advanced colon cancer, and it seemed to work well without making patients too sick.
Methodology
The study involved a phase II trial with patients receiving a combination of drugs through a specific timing schedule to reduce side effects.
Limitations
The study was limited to heavily pretreated patients, which may affect the generalizability of the results.
Participant Demographics
{"median_age":58,"gender_distribution":{"male":21,"female":14},"performance_status":{"0":26,"1":8,"2":1},"primary_tumor":{"colon":26,"rectum":9}}
Statistical Information
Confidence Interval
{"overall_response_rate":"9–36.8","complete_response":"0–8.4","partial_response":"6.8–33.3","stable_disease":"26.5–59.3","progression_disease":"18.6–50"}
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website